Alasztics Bálint, Gullai Nóra, Molvarec Attila, Rigó János
Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest Baross u. 27. 1082.
Orv Hetil. 2014 Nov 23;155(47):1860-6. doi: 10.1556/OH.2014.30042.
Preeclampsia is one of the most common and most serious complications of pregnancy and the management of this condition still challenges obstetricians. Despite intensive research the etiology of preeclampsia still remains unclear. At the beginning of the 2000s preeclampsia-related research was directed towards factors that influence angiogenesis. Most studies have been carried out on the placental growth factor and soluble fms-like tyrosine kinase-1. Most publications confirm the increased concentrations of antiangiogenic factors and decreased concentrations of proangiogenic factors in maternal blood samples in preeclampsia even before the onset of clinical symptoms. According to our current knowledge antiangiogenic proteins are responsible for the endothelial dysfunction in the symptomatic stage of the disease. Placental growth factor and soluble fms-like tyrosine kinase-1 may have important roles in the prediction and treatment of the disease. The point of care detection of placental growth factor and soluble fms-like tyrosine kinase-1 may be used to predict preeclampsia. Rapid tests are available to determine the serum levels of the two proteins. Removal of soluble fms-like tyrosine kinase-1 from maternal circulation is a potential treatment option for early onset preeclampsia.
子痫前期是妊娠最常见且最严重的并发症之一,对其进行管理仍然是产科医生面临的挑战。尽管进行了深入研究,但子痫前期的病因仍不明确。在21世纪初,子痫前期相关研究主要针对影响血管生成的因素。大多数研究围绕胎盘生长因子和可溶性fms样酪氨酸激酶-1展开。大多数出版物证实,即使在临床症状出现之前,子痫前期孕妇血液样本中抗血管生成因子浓度升高,而促血管生成因子浓度降低。根据我们目前的认识,抗血管生成蛋白在该疾病的症状期导致内皮功能障碍。胎盘生长因子和可溶性fms样酪氨酸激酶-1可能在该疾病的预测和治疗中发挥重要作用。对胎盘生长因子和可溶性fms样酪氨酸激酶-1进行即时检测可用于预测子痫前期。现有快速检测方法可测定这两种蛋白的血清水平。从母体循环中清除可溶性fms样酪氨酸激酶-1是早发型子痫前期的一种潜在治疗选择。